Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential.

Mediators of Inflammation
Olga Delarosa, Eleuterio Lombardo

Abstract

Mesenchymal stem cells (MSCs) are of special interest as therapeutic agents in the settings of both chronic inflammatory and autoimmune diseases. Toll-like receptors (TLR) ligands have been linked with the perpetuation of inflammation in a number of chronic inflammatory diseases due to the permanent exposure of the immune system to TLR-specific stimuli. Therefore, MSCs employed in therapy can be potentially exposed to TLR ligands, which may modulate MSC therapeutic potential in vivo. Recent results demonstrate that MSCs are activated by TLR ligands leading to modulation of the differentiation, migration, proliferation, survival, and immunosuppression capacities. However inconsistent results among authors have been reported suggesting that the source of MSCs, TLR stimuli employed or culture conditions play a role. Notably, activation by TLR ligands has not been reported to modulate the "immunoprivileged" phenotype of MSCs which is of special relevance regarding the use of allogeneic MSC-based therapies. In this review, we discuss the available data on the modulation of MSCs activity through TLR signalling.

References

Apr 2, 1999·Science·M F PittengerD R Marshak
Jan 7, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·K OhashiH Kolb
Nov 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·A OzinskyA Aderem
Jan 21, 2001·The Journal of Biological Chemistry·Y OkamuraJ F Strauss
May 15, 2001·American Journal of Physiology. Cell Physiology·M F TsanJ E White
Jan 10, 2002·The Journal of Experimental Medicine·Christian TermeerJan Christoph Simon
Feb 2, 2002·Experimental Hematology·Amelia BartholomewRonald Hoffman
May 8, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Geoffrey B JohnsonJeffrey L Platt
Jun 22, 2002·Nature·Yuehua JiangCatherine M Verfaillie
Dec 12, 2002·Molecular Biology of the Cell·Patricia A ZukMarc H Hedrick
Feb 22, 2003·Journal of Biomedical Science·Manas K MajumdarJoseph D Mosca
Oct 11, 2003·Experimental Hematology·Katarina Le BlancOlle Ringdén
Jun 16, 2004·The Journal of Experimental Medicine·Melissa W BouléIan R Rifkin
Oct 21, 2004·Blood·Sudeepta Aggarwal, Mark F Pittenger
Dec 15, 2004·Microbes and Infection·Chandrashekhar Pasare, Ruslan Medzhitov
Jun 4, 2005·Advances in Experimental Medicine and Biology·Chandrashekhar Pasare, Ruslan Medzhitov
Jun 4, 2005·Diseases of the Colon and Rectum·Damián García-OlmoJosé Antonio Rodríguez-Montes
Jan 18, 2006·Stem Cells·Kevin McIntoshJeffrey M Gimble
Feb 14, 2006·International Journal of Palliative Nursing·Katherine Froggatt
Feb 25, 2006·Cell·Shizuo AkiraOsamu Takeuchi
Apr 25, 2006·Experimental Cell Research·Ida Rasmusson
Aug 5, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alma J NautaWillem E Fibbe
Aug 12, 2006·Stem Cells·Hyun Hwa ChoJin Sup Jung
Oct 14, 2006·Blood·Meirav Pevsner-FischerDov Zipori
Nov 15, 2006·Current Pharmaceutical Design·K HoebeB Beutler
Nov 15, 2006·Current Pharmaceutical Design·Shunji IshiharaYoshikazu Kinoshita
Nov 15, 2006·Journal of Molecular and Cellular Cardiology·Shunsuke OhnishiNoritoshi Nagaya
Feb 6, 2007·Seminars in Immunology·Taro Kawai, Shizuo Akira
Apr 26, 2007·Nature Reviews. Immunology·Luke A J O'Neill, Andrew G Bowie

❮ Previous
Next ❯

Citations

Sep 10, 2010·Human Gene Therapy·Conrad P HodgkinsonVictor J Dzau
Jul 4, 2013·Stem Cells and Development·Mariano Di TrapaniMauro Krampera
Oct 15, 2011·Tissue Engineering. Part B, Reviews·Joyce DoornJan de Boer
Dec 15, 2010·Current Opinion in Gastroenterology·Nicholas A Manieri, Thaddeus S Stappenbeck
Jul 31, 2012·American Journal of Physiology. Cell Physiology·Michalis MastriTechung Lee
Apr 27, 2012·Experimental Diabetes Research·Roberto BassiPaolo Fiorina
Jan 10, 2012·Blood·Jeffery J AulettaAmelia M Bartholomew
Mar 22, 2013·World Journal of Stem Cells·Techung Lee
Apr 19, 2011·Seminars in Immunopathology·Ilaria Marigo, Francesco Dazzi
Apr 26, 2012·Nature Reviews. Immunology·Katarina Le Blanc, Dimitrios Mougiakakos
Jul 3, 2013·European Journal of Immunology·Friederike GiesekeIngo Müller
Jun 12, 2012·Current Opinion in Biotechnology·Olga DelaRosaEleuterio Lombardo
Nov 29, 2011·Trends in Molecular Medicine·Antje GeblerBarbara Seliger
Jan 16, 2016·Journal of Endodontics·Karim M Fawzy El-SayedChristof E Dörfer
Apr 9, 2013·Journal of Cellular and Molecular Medicine·Kyriaki ChatzivasileiouHermann Lang
Nov 16, 2011·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Hana Haleem-SmithRocky S Tuan
Oct 15, 2013·Stem Cells·Massimo GiulianiJean-Jacques Lataillade
Dec 19, 2015·Stem Cells International·Shihua WangRobert Chunhua Zhao
Sep 15, 2012·Biochimica Et Biophysica Acta·F van den AkkerJ P G Sluijter
Jan 9, 2013·Journal of the Neurological Sciences·Jeffrey A Cohen
May 2, 2014·Biochemical and Biophysical Research Communications·Hao YanTong Chen
Jun 18, 2016·Stem Cells International·Karim M Fawzy El-Sayed, Christof E Dörfer
Jun 30, 2016·International Journal of Molecular Sciences·Lisa PleyerRichard Greil

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
nuclear translocation

Software Mentioned

Cellerix

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.